Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1962
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1969 1
1972 1
1973 1
1975 1
1978 1
1980 1
1981 5
1982 7
1983 3
1984 8
1985 8
1986 17
1987 5
1988 1
1989 3
1990 3
1991 7
1992 5
1993 7
1994 9
1995 3
1996 8
1997 7
1998 10
1999 14
2000 15
2001 16
2002 22
2003 19
2004 26
2005 24
2006 32
2007 35
2008 28
2009 37
2010 28
2011 24
2012 26
2013 24
2014 29
2015 33
2016 35
2017 27
2018 28
2019 30
2020 36
2021 31
2022 39
2023 32
2024 25
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

749 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. Kimball AB, et al. Among authors: keefe d. Lancet. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. Lancet. 2023. PMID: 36746171 Clinical Trial.
Oocyte competency is the key to embryo potential.
Keefe D, Kumar M, Kalmbach K. Keefe D, et al. Fertil Steril. 2015 Feb;103(2):317-22. doi: 10.1016/j.fertnstert.2014.12.115. Fertil Steril. 2015. PMID: 25639967 Free article. Review.
Patient navigation across the cancer care continuum: An overview of systematic reviews and emerging literature.
Chan RJ, Milch VE, Crawford-Williams F, Agbejule OA, Joseph R, Johal J, Dick N, Wallen MP, Ratcliffe J, Agarwal A, Nekhlyudov L, Tieu M, Al-Momani M, Turnbull S, Sathiaraj R, Keefe D, Hart NH. Chan RJ, et al. Among authors: keefe d. CA Cancer J Clin. 2023 Nov-Dec;73(6):565-589. doi: 10.3322/caac.21788. Epub 2023 Jun 26. CA Cancer J Clin. 2023. PMID: 37358040 Free article. Review.
Editorial Comment.
Keefe DT. Keefe DT. J Urol. 2024 Apr;211(4):585. doi: 10.1097/JU.0000000000003859. Epub 2024 Feb 14. J Urol. 2024. PMID: 38353232 No abstract available.
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Gottlieb AB, Deodhar A, Mcinnes IB, Baraliakos X, Reich K, Schreiber S, Bao W, Marfo K, Richards HB, Pricop L, Shete A, Trivedi V, Keefe D, Papavassilis CC, Jagiello P, Papanastasiou P, Mease PJ, Lebwohl M. Gottlieb AB, et al. Among authors: keefe d. Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563. Acta Derm Venereol. 2022. PMID: 35146532 Free PMC article.
Telomere dynamics and reproduction.
Robinson LG Jr, Kalmbach K, Sumerfield O, Nomani W, Wang F, Liu L, Keefe DL. Robinson LG Jr, et al. Among authors: keefe dl. Fertil Steril. 2024 Jan;121(1):4-11. doi: 10.1016/j.fertnstert.2023.11.012. Epub 2023 Nov 21. Fertil Steril. 2024. PMID: 37993053 Free article. Review.
Trastuzumab-associated cardiotoxicity.
Keefe DL. Keefe DL. Cancer. 2002 Oct 1;95(7):1592-600. doi: 10.1002/cncr.10854. Cancer. 2002. PMID: 12237930 Free article. Review.
Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial.
Sigurgeirsson B, Browning J, Tyring S, Szepietowski JC, Rivera-Díaz R, Effendy I, Keefe D, Bruin G, Paguet B, Fu R, Hampele I, Reinhardt M, Patekar M. Sigurgeirsson B, et al. Among authors: keefe d. Dermatol Ther. 2022 Mar;35(3):e15285. doi: 10.1111/dth.15285. Epub 2022 Jan 8. Dermatol Ther. 2022. PMID: 34954841 Clinical Trial.
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, Papanastasiou P, Keefe D, Patekar M, Charef P, Zhang L, Cafoncelli S, Papavassilis C. Bodemer C, et al. Among authors: keefe d. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):938-947. doi: 10.1111/jdv.17002. Epub 2021 Jan 19. J Eur Acad Dermatol Venereol. 2021. PMID: 33068444 Free PMC article. Clinical Trial.
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D. Augustin M, et al. Among authors: keefe d. Br J Dermatol. 2022 Jun;186(6):942-954. doi: 10.1111/bjd.20971. Epub 2022 Apr 8. Br J Dermatol. 2022. PMID: 34981829 Clinical Trial.
749 results